Long-term statin safety and efficacy in secondary prevention: Can combination therapy improve outcomes?

Atherosclerosis Supplements

Volumn 4, Issue 5, 2003, Pages 11-16

  Wascher, Thomas C ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

ASA, Aspirin; Combination therapy; Coronary artery disease; Lipids; PPP trial; Pravastatin; Safety

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PERINDOPRIL; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; THROMBOCYTE SLOWING FACTOR; HYPOCHOLESTEROLEMIC AGENT;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; HUMAN; MEDICAL ETHICS; MONOTHERAPY; MORBIDITY; MORTALITY; MUSCLE DISEASE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; DRUG COMBINATION; META ANALYSIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICHOLESTEREMIC AGENTS; ASPIRIN; CORONARY ARTERIOSCLEROSIS; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 1442327345     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(03)90002-X     Document Type: Article

References (22)

1. Lawlor DA, Ebrahim S, Smith GD. Sex matters: secular and geographical trends in sex differences in coronary heart disease mortality. BMJ 2001;323:541-5.
2. Kuulasmaa K, Tunstall P, Dobson A, et al. Estimation of contribution of changes in classic risk factors to trends in coronary event rates across the WHO Monica project populations. Lancet 2000;355:675-87.
3. Foot DK, Lewis RP, Pearson TA, et al. Demographics and cardiology, 1950-2050. J Am Coll Cardiol 2000;35:1067-81.
4. Shepherd J, Cobbe M, Ford I, for the WOSCOPS study group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
5. The LIPID study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
6. Sacks F, Pfeffer M, Moye L, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
7. The 4S study group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin survival study. Lancet 1994;344:1383-9.
8. The HPS study group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. Lancet 2002;360:7-22.
9. Gotto AM. Statin therapy: Where are we ? Where do we go next? Am J Cardiol 2001;87(suppl):13B-18B.
10. The PPP investigators. Design, rationale and baseline characteristics of the prospective pravastatin pooling (PPP) project. Am J Cardiol 1995;76:899-905.
11. Simes J, Furberg CD, Braunwald E, et al. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J 2002;23:207-15
12. Unpublished data; Bristol-Myers Squibb.
13. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The prospective pravastatin pooling project. Circulation 2000;102:1893-900.
14. Byington RP, Davis BR, Plehn J, et al. Reduction of Stroke events with pravastatin. The prospective pravastatin pooling project. Circulation 2001;103:387-92.
15. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90.
16. Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, et al. Safety and tolerability of pravastatin in long-term clinical trials. Prospective pravastatin pooling project. Circulation 2002;105:2341-6.
17. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
18. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994;344:793-5.
19. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
20. The antithrombotic trialists collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
21. The HOPE Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
22. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled multicentre trial (the EUROPA study). Lancet 2003;362(9386):782-8.